Biolase Technology has finalized three regional distribution agreements in China.
This announcement follows an August 12 notification that the company had received regulatory approval to market its Waterlase MD products in China.
"Three regional agreements were signed in China with partners who have gained our strong confidence," said CEO David Mulder in a press release.
The first agreement was with Shanghai Haopu Medical Instruments for the eastern Chinese provinces and municipalities of Anhui, Fujian, Henan, Jiangsu, Jiangxi, Shandong, Shanghai, and Zhejiang.
The second agreement was with E-Maxdent, covering primarily the northern provinces and municipalities of Beijing, Gansu, Hebei, Heilongjian, Jilin, Liaoning, Qinghai, Shaanxi, Tianjin, Nei Mongol, Ningxia, Tibet, and Xinjiang.
The third agreement was with Advanced Medical Technology China for the southern provinces and municipalities of Guangdong, Guangxi, Hainan, Yunnan, Hunan, Guizhou, Sichuan, Chongqing, and Hubei.
"We have already started working on some initial demonstration unit orders, training, and marketing plans," Mulder said. "We expect a six- to nine-month ramp-up period and look forward to a promising future in China."
Copyright © 2009 DrBicuspid.com
